Influenza A Viral Infections Drug Development Pipeline Review, 2018

  • ID: 4530576
  • Report
  • Region: Global
  • 188 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • CEL-SCI Corp
  • Gemmus Pharma Inc
  • Medicago Inc
  • OPKO Health Inc
  • TechnoVax Inc
  • MORE

Influenza is an acute infection of the respiratory tract that predominately affects the nose, throat and bronchi, and less commonly the lungs. Influenza viruses have a single-stranded segmented RNA genome.

They belong to the family Orthomyxoviridae, and are categorized into three genera based on their core proteins A, B and C. Influenza A and B viruses are responsible for the majority of symptomatic cases of influenza in humans.

Influenza A viruses can be further categorized based on their expression of two viral surface proteins: hemagglutinin (H) and neuraminidase (N). These viruses are known to have high mutation rates, with frequent changes to the viral protein structure.

The total number of products under development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections is 54, 107, 58 and 31, respectively. Key companies operating in this pipeline space include Sanofi, Seqirus and NanoViricides.

This report “Influenza A Viral Infections Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for influenza A viral infections. It comprehensively documents therapeutics under development for influenza A H3N2, H1N1, H5N1 and H7N9 subtype infections, and features dormant and discontinued products.

Scope

  • Which companies are the most active within the pipeline for influenza A viral infections?
  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • CEL-SCI Corp
  • Gemmus Pharma Inc
  • Medicago Inc
  • OPKO Health Inc
  • TechnoVax Inc
  • MORE

1 Table of Contents

2 Introduction
2.1 Influenza A Viral Infections Report Coverage
2.2 Influenza A Virus, H3N2 Subtype Infections – Overview
2.3 Influenza A Virus, H1N1 Subtype Infections – Overview
2.4 Influenza A Virus, H5N1 Subtype Infections – Overview
2.5 Influenza A Virus, H7N9 Subtype Infections – Overview

3 Therapeutics Development
3.1 Influenza A Virus, H3N2 Subtype Infections
3.2 Influenza A Virus, H1N1 Subtype Infections
3.3 Influenza A Virus, H5N1 Subtype Infections
3.4 Influenza A Virus, H7N9 Subtype Infections

4 Therapeutics Assessment
4.1 Influenza A Virus, H3N2 Subtype Infections
4.2 Influenza A Virus, H1N1 Subtype Infections
4.3 Influenza A Virus, H5N1 Subtype Infections
4.4 Influenza A Virus, H7N9 Subtype Infections

5 Companies Involved in Therapeutics Development
5.1 Influenza A Virus, H3N2 Subtype Infections
5.2 Influenza A Virus, H1N1 Subtype Infections
5.3 Influenza A Virus, H5N1 Subtype Infections
5.4 Influenza A Virus, H7N9 Subtype Infections

6 Dormant Projects
6.1 Influenza A Virus, H3N2 Subtype Infections
6.2 Influenza A Virus, H1N1 Subtype Infections
6.3 Influenza A Virus, H5N1 Subtype Infections
6.4 Influenza A Virus, H7N9 Subtype Infections

7 Discontinued Products
7.1 Influenza A Virus, H3N2 Subtype Infections
7.2 Influenza A Virus, H1N1 Subtype Infections
7.3 Influenza A Virus, H5N1 Subtype Infections

8 Product Development Milestones
8.1 Influenza A Virus, H3N2 Subtype Infections
8.2 Influenza A Virus, H1N1 Subtype Infections
8.3 Influenza A Virus, H5N1 Subtype Infections
8.4 Influenza A Virus, H7N9 Subtype Infections

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

List of Tables
Table 1: Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections
Table 2: Number of Products under Development by Companies Influenza A Virus, H3N2 Subtype Infections
Table 3: Number of Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections
Table 4: Products under Development by Companies Influenza A Virus, H3N2 Subtype Infections
Table 5: Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections
Table 6: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections
Table 7: Number of Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections
Table 8: Number of Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections
Table 9: Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections
Table 10: Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections
Table 11: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections
Table 12: Number of Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections
Table 13: Number of Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections
Table 14: Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections
Table 15: Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections
Table 16: Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections
Table 17: Number of Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections
Table 18: Number of Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections
Table 19: Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections
Table 20: Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections
Table 21: Number of Products by Stage and Target, Influenza A Virus, H3N2 Subtype Infections
Table 22: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H3N2 Subtype Infections
Table 23: Number of Products by Stage and Route of Administration, Influenza A Virus, H3N2 Subtype Infections
Table 24: Number of Products by Stage and Molecule Type, Influenza A Virus, H3N2 Subtype Infections
Table 25: Number of Products by Stage and Target, Influenza A Virus, H3N2 Subtype Infections
Table 26: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H3N2 Subtype Infections
Table 27: Number of Products by Stage and Route of Administration, Influenza A Virus, H3N2 Subtype Infections
Table 28: Number of Products by Stage and Molecule Type, Influenza A Virus, H3N2 Subtype Infections
Table 29: Number of Products by Stage and Target, Influenza A Virus, H5N1 Subtype Infections
Table 30: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H5N1 Subtype Infections
Table 31: Number of Products by Stage and Route of Administration, Influenza A Virus, H5N1 Subtype Infections
Table 32: Number of Products by Stage and Molecule Type, Influenza A Virus, H5N1 Subtype Infections
Table 33: Number of Products by Stage and Target, Influenza A Virus, H7N9 Subtype Infections
Table 34: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H7N9 Subtype Infections
Table 35: Number of Products by Stage and Route of Administration, Influenza A Virus, H7N9 Subtype Infections
Table 36: Number of Products by Stage and Molecule Type, Influenza A Virus, H7N9 Subtype Infections
Table 37: Influenza A Virus, H3N2 Subtype Infections – Pipeline by AbbVie Inc
Table 38: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Adimmune Corp
Table 39: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Aphios Corp
Table 40: Influenza A Virus, H3N2 Subtype Infections – Pipeline by AusBio Ltd
Table 41: Influenza A Virus, H3N2 Subtype Infections – Pipeline by BioCryst Pharmaceuticals Inc
Table 42: Influenza A Virus, H3N2 Subtype Infections – Pipeline by BiondVax Pharmaceuticals Ltd
Table 43: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Cadila Healthcare Ltd
Table 44: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Celltrion Inc
Table 45: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Emergent BioSolutions Inc
Table 46: Influenza A Virus, H3N2 Subtype Infections – Pipeline by FluGen Inc
Table 47: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc
Table 48: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd
Table 49: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Johnson & Johnson
Table 50: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Medicago Inc
Table 51: Influenza A Virus, H3N2 Subtype Infections – Pipeline by MedImmune LLC
Table 52: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Mucosis BV (Inactive)
Table 53: Influenza A Virus, H3N2 Subtype Infections – Pipeline by NanoViricides Inc
Table 54: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Novavax Inc
Table 55: Influenza A Virus, H3N2 Subtype Infections – Pipeline by OPKO Health Inc
Table 56: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi
Table 57: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sanofi Pasteur SA
Table 58: Influenza A Virus, H3N2 Subtype Infections – Pipeline by Sarepta Therapeutics Inc
Table 59: Influenza A Virus, H3N2 Subtype Infections – Pipeline by SK Chemicals Co Ltd
Table 60: Influenza A Virus, H3N2 Subtype Infections – Pipeline by VBI Vaccines Inc
Table 61: Influenza A Virus, H1N1 Subtype Infections – Pipeline by AbbVie Inc

List of Figures
Figure 1: Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections
Figure 2: Number of Products under Development by Companies, Influenza A Virus, H3N2 Subtype Infections
Figure 3: Number of Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections
Figure 4: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections
Figure 5: Number of Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections
Figure 6: Number of Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections
Figure 7: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections
Figure 8: Number of Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections
Figure 9: Number of Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections
Figure 10: Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections
Figure 11: Number of Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections
Figure 12: Number of Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections
Figure 13: Number of Products by Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections
Figure 14: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections
Figure 15: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections
Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections
Figure 17: Number of Products by Routes of Administration, Influenza A Virus, H3N2 Subtype Infections
Figure 18: Number of Products by Stage and Routes of Administration, Influenza A Virus, H3N2 Subtype Infections
Figure 19: Number of Products by Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections
Figure 20: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections
Figure 21: Number of Products by Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections
Figure 22: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections
Figure 23: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections
Figure 24: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections
Figure 25: Number of Products by Top 10 Routes of Administration, Influenza A Virus, H3N2 Subtype Infections
Figure 26: Number of Products by Stage and Top 10 Routes of Administration, Influenza A Virus, H3N2 Subtype Infections
Figure 27: Number of Products by Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections
Figure 28: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections
Figure 29: Number of Products by Top 10 Targets, Influenza A Virus, H5N1 Subtype Infections
Figure 30: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H5N1 Subtype Infections
Figure 31: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H5N1 Subtype Infections
Figure 32: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H5N1 Subtype Infections
Figure 33: Number of Products by Routes of Administration, Influenza A Virus, H5N1 Subtype Infections
Figure 34: Number of Products by Stage and Routes of Administration, Influenza A Virus, H5N1 Subtype Infections
Figure 35: Number of Products by Top 10 Molecule Types, Influenza A Virus, H5N1 Subtype Infections
Figure 36: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H5N1 Subtype Infections
Figure 37: Number of Products by Targets, Influenza A Virus, H7N9 Subtype Infections
Figure 38: Number of Products by Stage and Targets, Influenza A Virus, H7N9 Subtype Infections
Figure 39: Number of Products by Mechanism of Actions, Influenza A Virus, H7N9 Subtype Infections
Figure 40: Number of Products by Stage and Mechanism of Actions, Influenza A Virus, H7N9 Subtype Infections
Figure 41: Number of Products by Routes of Administration, Influenza A Virus, H7N9 Subtype Infections
Figure 42: Number of Products by Stage and Routes of Administration, Influenza A Virus, H7N9 Subtype Infections
Figure 43: Number of Products by Molecule Types, Influenza A Virus, H7N9 Subtype Infections
Figure 44: Number of Products by Stage and Molecule Types, Influenza A Virus, H7N9 Subtype Infections

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Adimmune Corp
  • Akshaya Bio Inc
  • Altimmune Inc
  • Antigen Express Inc
  • Aphios Corp
  • AusBio Ltd
  • Beijing Minhai Biotechnology Co Ltd
  • BioCryst Pharmaceuticals Inc
  • BiondVax Pharmaceuticals Ltd
  • Cadila Healthcare Ltd
  • Celltrion Inc
  • CEL-SCI Corp
  • Cilian AG
  • Cocrystal Pharma Inc
  • ContraFect Corp
  • Curevac AG
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Etubics Corp
  • FluGen Inc
  • Gemmus Pharma Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Hemispherx Biopharma Inc
  • iBio Inc
  • Inovio Pharmaceuticals Inc
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • Kineta Inc
  • Kyowa Hakko Kirin Co Ltd
  • Lakewood-Amedex Inc
  • Medicago Inc
  • Medigen Vaccine Biologics Corp
  • MedImmune LLC
  • Microbiotix Inc
  • Moderna Therapeutics Inc
  • Mucosis BV
  • NanoBio Corp
  • NanoViricides Inc
  • Novavax Inc
  • Ology Bioservices Inc
  • OPKO Health Inc
  • PaxVax Inc
  • PeptiDream Inc
  • Recce Ltd
  • Sanofi
  • Sanofi Pasteur SA
  • Sarepta Therapeutics Inc
  • Shionogi & Co Ltd
  • SK Chemicals Co Ltd
  • TechnoVax Inc
  • Touchlight Genetics Ltd
  • Vaccibody AS
  • Vaxart Inc
  • Vaxine Pty Ltd
  • VBI Vaccines Inc
  • VirionHealth Ltd
  • Visterra Inc
  • Vivaldi Biosciences Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll